FOLD
Amicus Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +18.2% ·
share flow +10.3% ·
net new positions +15.4%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q1 2026 | 106 | -6 | 206.15M | $2.98B | +6 | −13 |
| Q4 2025 | 112 | +4 | 192.14M | $2.74B | +5 | — |
| Q3 2025 | 19 | -1 | 150.66M | $1.19B | — | −2 |
| Q2 2025 | 18 | 0 | 135.88M | $778.62M | — | — |
| Q1 2025 | 15 | +2 | 70.64M | $576.46M | +2 | — |
| Q4 2024 | 13 | -1 | 63.65M | $599.56M | — | −1 |
| Q3 2024 | 13 | +2 | 42.84M | $457.59M | +2 | — |
| Q2 2024 | 11 | — | 38.85M | $385.40M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 23.96M | +13.5% | $255.94M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 23.96M | +13.5% | $255.94M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Wellington Management ✦ | 23.96M | +13.5% | $255.94M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 23.96M | +13.5% | $255.94M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 23.96M | +13.5% | $255.94M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 23.96M | +13.5% | $255.94M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 23.96M | +13.5% | $255.94M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 6.60M | +1.2% | $70.50M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 6.60M | +1.2% | $70.50M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 3.63M | +20.3% | $38.77M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 3.63M | +20.3% | $38.77M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Norges Bank ✦ (passive) | 2.92M | 0.0% | $31.24M | 0.0% | Held | 2 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 1.34M | -3.5% | $14.33M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 1.34M | -3.5% | $14.33M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Point72 Asset Management ✦ | 1.27M | New | $13.53M | 0.0% | New | 1 | SEC ↗ |
| 16 | PRIMECAP Management ✦ | 1.03M | -2.2% | $10.99M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Renaissance Technologies ✦ | 769.30K | +21.7% | $8.22M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 670.44K | +651.0% | $7.16M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 19 | Millennium Management ✦ | 412.56K | -78.2% | $4.41M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 125.96K | -7.0% | $1.35M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 88.85K | +1.4% | $948,875 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 88.85K | +1.4% | $948,875 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 23 | Marshall Wace ✦ | 20.60K | New | $220,008 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $13.53M | 0.0% |
| Marshall Wace | $220,008 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 296 holders, 325.04M shares, $4.48B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.